Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casein glycomacropeptide protein substitute is a medical food formulated as a protein replacement for individuals with phenylketonuria (PKU), an inherited metabolic disorder requiring strict dietary phenylalanine restriction[1][4][5]. **CGMP** is a peptide derived from kappa-casein during cheese production; it is naturally low in phenylalanine but deficient in several essential amino acids (histidine, leucine, methionine, tryptophan, tyrosine) and therefore must be supplemented accordingly for complete nutritional adequacy[1][4]. CGMP-based substitutes offer an alternative to synthetic free amino acid (L-AA) protein substitutes, with potential advantages including improved palatability and possible metabolic benefits such as slower amino acid absorption and improved nitrogen retention[1][5]. Products are typically further fortified with vitamins, minerals, and sometimes other nutrients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on casein glycomacropeptide protein substitute.